Reynolds Delgado, MD
Cardiovascular Disease · Houston, TXNPI 1720024466
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $386,179 of the $470,563 with a category attached, or 82.1%. 55 manufacturers reported payments, led by Boehringer Ingelheim at 32.0% of the total. Reporting peaked in 2019 at $101,175 and has fallen 55.9% since, to $44,570 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,347 payments — averaging $349.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$150K
- Akcea Therapeutics, Inc.$70K
- Merck$49K
- AstraZeneca$49K
- Johnson & Johnson$35K
- Pfizer$30K
- plus $87K from 49 others
Across 26 payments — averaging $6066.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$157K
- Adagio Medical, Inc.$700
Across 10 payments — averaging $46,146 each. An ownership or investment interest held by the physician or an immediate family member.
- Procyrion, Inc.$461K
What the payments were for
- Consulting fees$12,8283%
- Speaking & faculty fees$386,17982%
- Travel & lodging$42,4529%
- Food & beverage$28,9356%
- Education$1520%
- Entertainment$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$174,958
- VERQUVO$86,690
- TEGSEDI$66,264
- XARELTO$32,331
- FARXIGA$26,808
- VYNDAQEL$25,056
- WAINUA$19,090
- ENTRESTO$14,863
- Kerendia$13,779
- AMVUTTRA$5,755
- Attruby$2,914
- CARDIOMEMS$1,460
- iCLAS Continuous Lesion Ablation System$1,050
- OPTIMIZER$821
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$360
- HeartMate 3 Left Ventricular Dev$252
- HeartMate 3 Left Ventricular Assist Device$230
- HeartMate$161
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$159
- ATRICLIP LAA EXCLUSION SYSTEM$159
How this compares
$470,563 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 22 | $497,541 |
| VyndaqelTafamidis Meglumine | 11 | $245,655 |
| EliquisApixaban | 159 | $180,566 |
| JardianceEmpagliflozin | 147 | $162,892 |
| EntrestoSacubitril/Valsartan | 105 | $148,512 |
| CamzyosMavacamten | 12 | $99,112 |
| XareltoRivaroxaban | 80 | $81,628 |
| FarxigaDapagliflozin Propanediol | 47 | $61,870 |
| VerquvoVericiguat | 23 | $34,807 |
| Repatha SureclickEvolocumab | 30 | $31,078 |
| KerendiaFinerenone | 29 | $28,484 |
| Tacrolimus | 62 | $13,015 |
| Metoprolol Succinate | 655 | $11,940 |
| Sirolimus | 16 | $9,990 |
| Atovaquone | 14 | $8,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $30,257 | $923,762192 claims |
| Boehringer IngelheimJardiance | $150,387 | $162,892147 claims |
| NovartisEntresto | $15,241 | $148,512105 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,049 | $99,11212 claims |
| Johnson & JohnsonXarelto | $35,127 | $81,62880 claims |
| AstraZenecaFarxiga, Brilinta | $48,524 | $69,23163 claims |
| MerckVerquvo | $48,941 | $34,80723 claims |
| BayerKerendia | $14,504 | $28,48429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
- Dipan ShahHouston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.